Tadalafil Tablet, Film Coated
Product Images NDC 71610-581

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-581). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 10 mg (71610 0581 04)

Tadalafil 10 mg film-coated tablets packaging label showing 4 tablets per package. The label includes the proprietary and generic name Tadalafil USP, NDC number 71610-0581-04, manufacturer Anneal Pharmaceuticals LLC, and repackager Aphena Pharma Solutions - Tennessee, LLC. Storage instructions and prescription-only designation are also visible.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

10 (Tadalafil Tablets Usp 1)

Chemical structure of Tadalafil, showing its molecular framework with rings and key functional groups consistent with its known structure.*

FDA Label Image

10 (Tadalafil Tablets Usp 2)

A set of four line graphs displaying the difference in blood pressure measurements (Tadalafil minus Placebo) over time in hours. The graphs show changes in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure, with the y-axis measuring difference in mmHg and the x-axis measuring time in hours up to 96 hours.*

FDA Label Image

10 (Tadalafil Tablets Usp 3)

Two line graphs showing the effect on standing and supine systolic blood pressure over 24 hours post-dose, comparing Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The vertical axis shows blood pressure in mmHg, while the horizontal axis shows time in hours after dosing.*

FDA Label Image

10 (Tadalafil Tablets Usp 4)

A line graph depicting changes in systolic blood pressure (mmHg) over 12 hours following administration of tadalafil or placebo alongside doxazosin. The x-axis shows time after administration in hours, and the y-axis shows systolic blood pressure. Four lines represent different treatment groups: 20 mg tadalafil at 08:00 with doxazosin, placebo at 08:00 with doxazosin, 20 mg tadalafil at 20:00 with doxazosin, and placebo at 20:00 with doxazosin.*

FDA Label Image

10 (Tadalafil Tablets Usp 5)

A pharmacokinetic line graph showing plasma tadalafil concentration (mcg/L) over time (hours) for three dosing scenarios: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The graph includes error bars indicating variability at each time point and a legend identifying each dosing line.*

FDA Label Image

10 (Tadalafil Tablets Usp 6)

A line graph showing the change from baseline in IPSS total score over 12 weeks comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change in IPSS score, with decreases indicating improvement. Two lines track scores for Tadalafil and placebo groups, indicating a greater reduction with Tadalafil at all measured time points. A statistical significance note (p<0.01) is displayed on the graph.*

FDA Label Image

10 (Tadalafil Tablets Usp 7)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment duration, comparing Tadalafil 5 mg and placebo groups. The graph displays a greater decrease in IPSS score for Tadalafil 5 mg, with statistical significance noted at weeks 4 and 12 (p<0.01).*

FDA Label Image

10 (Tadalafil Tablets Usp 8)

A line graph depicting least squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride groups. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows change from baseline values. Data points show decreases for both groups, with Tadalafil/Finasteride showing greater reduction.*

FDA Label Image

10 (Tadalafil Tablets Usp 9)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. The graph compares Tadalafil 5 mg (solid circles) and placebo (open triangles). The y-axis indicates the change in score, and the x-axis represents treatment duration in weeks. Tadalafil shows a greater decrease in IPSS score compared to placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.